Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Sichuan Baili Pharmaceutical Co., Ltd. appears in 57 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
57 shownA Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)NCT07729956 · lead sponsor · 2026-09-02
RECRUITINGA Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast CancerNCT07678957 · lead sponsor · 2026-08-31
RECRUITINGA Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)NCT07640789 · lead sponsor · 2026-08-28
RECRUITINGA Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsNCT07753226 · lead sponsor · 2026-08-18
RECRUITINGA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)NCT07642024 · lead sponsor · 2026-07-24
RECRUITINGA Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung CancerNCT07654400 · lead sponsor · 2026-07-09
RECRUITINGA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)NCT07648914 · lead sponsor · 2026-07-06
RECRUITINGA Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)NCT07502300 · lead sponsor · 2026-06-15
RECRUITINGA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerNCT07518173 · lead sponsor · 2026-04-21
RECRUITINGA Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCNCT07264816 · lead sponsor · 2026-02-03
RECRUITINGA Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsNCT07274852 · lead sponsor · 2025-12-10
RECRUITINGA Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid TumorsNCT07232420 · lead sponsor · 2025-11-11
RECRUITINGA Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCNCT07178795 · lead sponsor · 2025-09-29
RECRUITINGA Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid TumorsNCT07056556 · lead sponsor · 2025-07-30
RECRUITINGA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerNCT06891833 · lead sponsor · 2025-06-05
RECRUITINGA Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant TherapyNCT06830889 · lead sponsor · 2025-06-03
RECRUITINGA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast CancerNCT06957886 · lead sponsor · 2025-05-15
RECRUITINGA Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid ArthritisNCT06857227 · lead sponsor · 2025-03-17
RECRUITINGA Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)NCT06838273 · lead sponsor · 2025-02-24
RECRUITINGA Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsNCT06609187 · lead sponsor · 2024-10-30
RECRUITINGA Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid TumorsNCT06612840 · lead sponsor · 2024-10-16
RECRUITINGA Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsNCT06493864 · lead sponsor · 2024-08-26
RECRUITINGA Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid TumorsNCT06503783 · lead sponsor · 2024-08-24
RECRUITINGA Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid TumorsNCT06505824 · lead sponsor · 2024-08-02
RECRUITINGA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast CancerNCT06471205 · lead sponsor · 2024-08-02
RECRUITINGA Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerNCT06498986 · lead sponsor · 2024-07-31
RECRUITINGA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsNCT06475300 · lead sponsor · 2024-06-25
RECRUITINGA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung CancerNCT06437509 · lead sponsor · 2024-06-13
RECRUITINGA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsNCT05956587 · lead sponsor · 2024-01-29
RECRUITINGA Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast CancerNCT06042894 · lead sponsor · 2023-12-12
RECRUITINGA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung CancerNCT05924841 · lead sponsor · 2023-11-10
RECRUITINGA Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsNCT05470348 · lead sponsor · 2022-08-11
RECRUITINGA Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsNCT05461768 · lead sponsor · 2022-08-09
RECRUITINGA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorNCT05194982 · lead sponsor · 2021-11-29
RECRUITINGA Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNCT07641855 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGA Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07827261 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGA Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)NCT07739186 · lead sponsor · 2026-08-01
NOT_YET_RECRUITINGA Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)NCT07739199 · lead sponsor · 2026-08-01
NOT_YET_RECRUITINGA Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)NCT06500026 · lead sponsor · 2024-08-07
ACTIVE_NOT_RECRUITINGA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)NCT06382142 · lead sponsor · 2024-06-21
ACTIVE_NOT_RECRUITINGA Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerNCT06445400 · lead sponsor · 2024-06-19
ACTIVE_NOT_RECRUITINGA Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)NCT06382116 · lead sponsor · 2024-05-22
ACTIVE_NOT_RECRUITINGA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)NCT06382129 · lead sponsor · 2024-05-17
ACTIVE_NOT_RECRUITINGA Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerNCT06316531 · lead sponsor · 2024-05-08
ACTIVE_NOT_RECRUITINGA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)NCT06343948 · lead sponsor · 2024-04-24
ACTIVE_NOT_RECRUITINGA Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06114511 · lead sponsor · 2024-04-24
ACTIVE_NOT_RECRUITINGA Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerNCT05949606 · lead sponsor · 2023-10-30
ACTIVE_NOT_RECRUITINGA Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid TumorsNCT05949619 · lead sponsor · 2023-09-04
ACTIVE_NOT_RECRUITINGA Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerNCT05880706 · lead sponsor · 2023-07-19
ACTIVE_NOT_RECRUITINGA Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaNCT05943795 · lead sponsor · 2023-07-14
ACTIVE_NOT_RECRUITINGA Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid TumorsNCT05339685 · lead sponsor · 2022-05-20
ACTIVE_NOT_RECRUITINGSI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.NCT05020769 · lead sponsor · 2022-01-06
ACTIVE_NOT_RECRUITINGSI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.NCT05020457 · lead sponsor · 2021-12-07
ACTIVE_NOT_RECRUITINGA Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast CancerNCT05160545 · lead sponsor · 2021-11-26
ACTIVE_NOT_RECRUITINGA Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid TumorsNCT05039931 · lead sponsor · 2021-09-15
WITHDRAWNA Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsNCT04606472 · lead sponsor · 2020-11-10
ACTIVE_NOT_RECRUITINGA Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsNCT04603287 · lead sponsor · 2020-04-17
ACTIVE_NOT_RECRUITINGDrugs studied in this sponsor's trials
23 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Sichuan Baili Pharmaceutical Co., Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
carboplatin6
docetaxel6
osimertinib4
capecitabine3
cisplatin3
pemetrexed3
pertuzumab3
ado-trastuzumab emtansine2
carboplatin RxCUI 40048 · Lead sponsor in 6 linked trial(s) · 4 currently recruiting
6 trials
docetaxel RxCUI 72962 · Lead sponsor in 6 linked trial(s) · 2 currently recruiting
6 trials
osimertinib RxCUI 1721560 · Lead sponsor in 4 linked trial(s) · 3 currently recruiting
4 trials
capecitabine RxCUI 194000 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting
3 trials
cisplatin RxCUI 2555 · Lead sponsor in 3 linked trial(s) · 2 currently recruiting
3 trials
pemetrexed RxCUI 68446 · Lead sponsor in 3 linked trial(s) · 2 currently recruiting
3 trials
pertuzumab RxCUI 1298944 · Lead sponsor in 3 linked trial(s) · 2 currently recruiting
3 trials
ado-trastuzumab emtansine RxCUI 1371041 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting
2 trials
eribulin RxCUI 1045453 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
gemcitabine RxCUI 12574 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
paclitaxel RxCUI 56946 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting
2 trials
pembrolizumab RxCUI 1547545 · Lead sponsor in 2 linked trial(s) · 2 currently recruiting
2 trials
tislelizumab RxCUI 2677426 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting
2 trials
trastuzumab RxCUI 224905 · Lead sponsor in 2 linked trial(s) · 2 currently recruiting
2 trials
vinorelbine RxCUI 39541 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
abiraterone RxCUI 1100072 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
atezolizumab RxCUI 1792776 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
etoposide RxCUI 4179 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
olaparib RxCUI 1597582 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
pemetrexed disodium RxCUI 282443 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
topotecan RxCUI 57308 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
lead sponsor57
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.